Amphotericin B intralipid formulation: stability and particle size.

Abstract

Amphotericin B remains the drug of choice for treating systemic fungal infections, although toxicity limits its clinical use. Some studies reported the use of Intralipid deoxycholate amphotericin B as an alternative delivery system. An in-vitro study was performed to assess the compatibility of deoxycholate amphotericin B in Intralipid. With two types of dilution of deoxycholate amphotericin B (in 5% dextrose and Intralipid or in Intralipid alone) the solution stability was not constant with a clear yellow precipitate. We observed an increase in the size of the particles (1.5-4-fold). In light of these results Intralipid deoxycholate amphotericin B should not be routinely administered.